Background. The recently published SSO-ASTRO consensus guideline on margins concluded ''no ink on tumor'' is the standard for an adequate margin. This study was conducted to determine how this guideline is aligned with current clinical practice. Methods. A survey was sent to 3057 members of the American Society of Breast Surgeons. Questions assessed respondents' clinical practice type and duration, familiarity with the guideline, and preferences for margin re-excision. Results. Of those surveyed, 777 (25 %) responded. Most (92 %) indicated familiarity with the guideline. Of these respondents, the majority (n = 678, or 94.7 %) would reexcise all or most of the time when tumor extended to the inked margin. Very few (n = 9, or 1.3 %) would re-excise all or most of the time when tumor was within 2 mm of the margin. Over 12 % (n = 90) would re-excise all or most of the time for a triple-negative tumor within 1 mm of the margin, whereas 353 (49.6 %) would re-excise all or most of the time when imaging and pathology were discordant, and tumor was within 1 mm of multiple margins. Finally, 330 (45.8 %) would re-excise all or most of the time when multiple foci of ductal carcinoma in situ extended to within
ABSTRACT
Background. The recently published SSO-ASTRO consensus guideline on margins concluded ''no ink on tumor'' is the standard for an adequate margin. This study was conducted to determine how this guideline is aligned with current clinical practice. Methods. A survey was sent to 3057 members of the American Society of Breast Surgeons. Questions assessed respondents' clinical practice type and duration, familiarity with the guideline, and preferences for margin re-excision. Results. Of those surveyed, 777 (25 %) responded. Most (92 %) indicated familiarity with the guideline. Of these respondents, the majority (n = 678, or 94.7 %) would reexcise all or most of the time when tumor extended to the inked margin. Very few (n = 9, or 1.3 %) would re-excise all or most of the time when tumor was within 2 mm of the margin. Over 12 % (n = 90) would re-excise all or most of the time for a triple-negative tumor within 1 mm of the margin, whereas 353 (49.6 %) would re-excise all or most of the time when imaging and pathology were discordant, and tumor was within 1 mm of multiple margins. Finally, 330 (45.8 %) would re-excise all or most of the time when multiple foci of ductal carcinoma in situ extended to within 1 mm of multiple inked margins. Conclusions. Surgeons are in agreement to re-excise margins when tumor touches ink and generally not to perform re-excisions when tumor is close to (but not touching) the inked margin. For more complex scenarios, surgeons are utilizing their individual clinical judgment to determine the need for re-excision.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06 trial and five other large, randomized trials demonstrated that overall survival is equivalent in patients with early-stage breast cancer undergoing mastectomy or breast-conserving therapy (BCT). [1] [2] [3] [4] [5] [6] Each trial defined BCT as excision of the primary tumor with a margin of normal breast tissue followed by whole-breast irradiation (WBI). However, width of the margin of normal breast tissue required at excision varied across trials. While the NSABP B-06 trial defined a negative margin as ''no tumor on ink'' the Milan trials required quadrantectomy with excision of a 2-to 3-cm margin of grossly normal tissue as well as overlying skin and underlying fascia. 1, 2 BCT requires tumor excision with negative margins to reduce risk of ipsilateral breast tumor recurrence (IBTR). However, the width of normal tissue required for a negative margin to be deemed adequate has varied widely in clinical practice. 7, 8 In nearly half of patients who return to the operating room for margin re-excision, the reason is to achieve a wider margin of normal breast tissue. 9 Returning to the operating room for re-excision of margins has been associated with increased surgical complications, increased stress and anxiety for patients and their families, increased healthcare costs, and even an increased rate of contralateral prophylactic mastectomy. [10] [11] [12] published a consensus guideline on margins for breastconserving surgery (BCS) with WBI in stage I and II invasive breast cancer. 13 14 Data for patients who received neoadjuvant chemotherapy, patients who did not undergo radiation therapy, and patients for whom radiation other than WBI was planned were excluded from the analysis. This multidisciplinary panel concluded that the standard for an adequate margin in patients undergoing BCS with WBI should be ''no ink on tumor. '' In response to publication of this guideline, some have advocated for a multidisciplinary evaluation of each case to determine the adequacy of margin width on the basis of clinical, pathologic, and treatment variables. 15 However, little is known about national practice patterns since publication of the SSO-ASTRO guideline on margins. The current study was conducted to evaluate current practice patterns among breast surgeons since publication of the guideline.
METHODS
The current study was reviewed by the ASBrS Research Committee and approved by the ASBrS Board of Directors. A link to an 8-question survey ( Fig. 1) 
RESULTS
Of the 3057 ASBrS members invited to participate, 777 (25 %) responded to the survey. Of these respondents, 557 (71.7 %) were in private practice and 220 (28.3 %) were in an academic practice setting. A total of 360 respondents (46.4 %) were general or oncologic surgeons who perform breast surgery as part of their practice, and 417 (53.6 %) were surgeons focusing only on breast diseases (Fig. 2a) . One hundred ten respondents (14.2 %) had been in practice for 5 years or less, 96 (12.4 %) for 6-10 years, 126 (16.2 %) for 11-15 years, 106 (13.6 %) for 16-20 years, 138 (17.8 %) for 21-25 years, 88 (11.3 %) for 26-30 years, and 113 (14.5 %) for more than 30 years (Fig. 2b) . The majority of respondents (714/777, 91.9 %) indicated familiarity with the recently published consensus guideline.
The case presented in scenario 1 was a woman with a 1.2-cm lesion with a small satellite lesion whose surgical pathology evaluation showed a 1.4-cm, high-grade invasive ductal carcinoma positive for estrogen receptor (ER) and progesterone receptor (PR), negative for HER2, with invasive tumor extending to the inked superior margin. In this scenario, 678 respondents (94.7 %) familiar with the guideline indicated they would perform re-excision most or all of the time, whereas 38 (5.3 %) indicated they would reexcise some of the time, infrequently, or never (Fig. 3a) .
The case presented in scenario 2 was a woman with an 8-mm unifocal lesion on imaging whose surgical pathology evaluation showed an 8-mm, low-grade invasive ductal carcinoma positive for ER and PR, negative for HER2, with invasive tumor within 2 mm of the inked margin. In this scenario, only 9 respondents (1.3 %) indicated they would perform re-excision most or all of the time, 17 (2.4 %) indicated they would re-excise some of the time, and 691 (96.3 %) indicated they would perform re-excision infrequently or never (Fig. 3b) .
The case in scenario 3 was a woman with a 2.3-cm lesion whose surgical pathology evaluation showed a 2.5-cm, high-grade, triple-negative, invasive ductal carcinoma with a single focus of invasive tumor within 1 mm of the inked margin. In this scenario, 90 respondents (12.4 %) indicated they would perform re-excision all or most of the time, 95 (13.1 %) indicated they would re-excise some of the time, and 540 (74.5 %) indicated they would perform re-excision infrequently or never (Fig. 3c) .
In scenario 4 was a woman with a 2.4-cm unifocal lesion on imaging whose surgical pathology evaluation showed a 7-cm invasive lobular carcinoma positive for ER and PR, negative for HER2, with invasive tumor within 1 mm of the inferior, anterior, and superior margins. In this scenario, 353 respondents (49.6 %) indicated they would perform reexcision all or most of the time, 106 (14.9 %) indicated they would re-excise some of the time, and 253 (35.5 %) indicated they would perform re-excision infrequently or never (Fig. 3d ). 
FIG. 1 Survey instrument
The case in scenario 5 was a woman with a 1.6-cm unifocal lesion whose surgical pathology evaluation showed a 1.9-cm invasive ductal carcinoma positive for ER, negative for PR, and positive for HER2 with extensive DCIS, multiple foci of invasive carcinoma within 2 mm of the inked margin, a focus of DCIS extending to 1 mm of the inked margin, and ducts with cautery artifact at the inked margin. In this scenario, 330 respondents (45.8 %) indicated they would perform re-excision all or most of the time, 123 (17.1 %) indicated they would re-excise some of the time, and 267 (37.1 %) indicated they would perform re-excision infrequently or never (Fig. 3e) .
Comparison by practice type revealed that surgeons in an academic practice were only slightly more likely to be familiar with the recently published guideline than surgeons in private practice (95 vs. 90.7 %, P = 0.046). Breast-only surgeons were more likely to be familiar with the guideline than general or oncologic surgeons who perform breast surgery (97.4 vs. 85.6 %, P \ 0.001). However, responses to the five clinical scenarios did not differ by practice type. Analysis of responses by clinical practice duration showed that surgeons in practice for more than 25 years were more likely than surgeons with 25 or fewer years in practice to indicate they would perform margin re-excision for the patient with triple-negative breast cancer and a close margin (scenario 3) (P = 0.016).
DISCUSSION
Results of this survey of ASBrS members showed the vast majority of respondents were familiar with the SSO-ASTRO consensus guideline on margins for BCS with WBI in patients with stage I and II invasive breast cancer, and most would appropriately re-excise margins when there was ink on tumor. Furthermore, most responded they would not re-excise margins when tumor was close to (but not touching) the inked margin, in agreement with the guideline. However, for more complex scenarios, respondents utilized their individual clinical judgment to determine whether re-excision was needed.
These data suggest a change in perceptions on the definitions of an adequate margin from prior to publication of the SSO-ASTRO guideline on margins. For example, in 2005 Taghian and colleagues published results of a survey of radiation oncologists revealing that nearly 46 % of North American radiation oncologists and 27.6 % of European radiation oncologists considered ''no tumor cells on the ink'' an adequate margin, whereas others required margins of 1 mm (7.4 % of North American and 11.2 % of European radiation oncologists) or 2 mm (21.8 % of North American and 8.8 % of European radiation oncologists). 7 More recently, Azu et al. utilized the Los Angeles and Detroit Surveillance, Epidemiology, and End Results registries to demonstrate that wide variations existed amongst surgeons with respect to consideration of an adequate margin width. 8 These authors found that 11 % of surgeons used a standard of ''tumor not touching ink,'' whereas 42 % used a margin width of 1-2 mm, 28 % used a width of C5 mm, and 19 % used a width of [1 cm. These marked variations in clinical practice prior to publication of the SSO-ASTRO guideline prompted us to question if surgical practice has changed since the guideline was published.
In the current study, undertaken 5 months following publication of the guideline, surgeons were in agreement about the need to return to the operating room for re-excision of margins when tumor was at the inked margin. This is not surprising, because data suggest that when tumor is present at the inked margin (positive margin), patients have a greater than two times increase of IBTR compared with patients with close or negative margins. 13, 16, 17 Furthermore, this increased recurrence risk with positive margins is not reversed (or negated) by the addition of a radiation boost or endocrine therapy. 13, 14, 18 Thus, it is not surprising that surgeons stated they would perform re-excision when there was ink on tumor (positive margin). Surgeons in our current study were also in agreement about the lack of necessity of re-excision when a unifocal invasive tumor with favorable biological features was close to the margin but had no ink on tumor. In our survey, only 9 respondents (1.3 %) indicated they would perform reexcision all of the time or most of the time in this scenario. This finding suggests a marked shift in alignment of the definition of a negative margin from that described in the above-aforementioned studies undertaken prior to publication of the guideline. 7, 8 Our survey revealed less consensus among respondents regarding need for re-excision in a patient with a unifocal tumor of the more aggressive triple-negative subtype close to the margin. In this scenario, 90 surgeons (12.4 %) indicated they would return to the operating room for reexcision all of the time or most of the time. meta-analysis on which the SSO-ASTRO guideline was based produced no clear evidence that unfavorable biology was mitigated by wider negative margins, our survey indicates that surgeons continue to consider tumor subtype in decision making regarding the need to perform reexcision. 13 There was much less agreement among respondents regarding need for re-excision in more complex scenarios, including the scenario of a patient with significant discordance between tumor size on preoperative imaging and pathologic size and tumor close to multiple margins (scenario 4) and the scenario of a woman with extensive DCIS with multiple foci of DCIS extending to within 1 mm of the margins and ducts with cautery artifact at the margin (scenario 5). It is not surprising that surgeon practice would vary widely in these complex scenarios. Patients whose tumors have an extensive intraductal component have been found to have a higher likelihood of significant residual DCIS in re-excised breast tissue and a higher likelihood of additional foci of DCIS located 2 cm or more from the index cancer. 19, 20 Although the consensus panel that developed the SSO-ASTRO guideline did not support consistently requiring a margin greater than no ink on tumor for patients with extensive intraductal component, the panel did recommend consideration of postoperative mammography in such patients to assess for residual calcifications. 13 The panel did note that patients with an extensive intraductal component may be selected for reexcision based on high-risk features, including young age and multiple close margins, consistent with many responses from this survey. However, the consensus panel was convened to specifically focus on margins for patients with invasive cancer receiving WBI. Another panel has been convened to provide a guideline for DCIS.
The endorsement of the SSO-ASTRO guideline on margins by ASCO emphasized the importance of performing postoperative mammography to assess for microcalcifications and called for flexibility in application of the guideline based on clinical judgment. 21 In addition, Hunt and colleagues emphasized that each case should be evaluated by the multidisciplinary team including the surgeon, pathologist, breast imager, and radiation oncologist to ensure that clinical, pathologic, and treatment variables are considered in determining adequate margin width. 15 Our study confirms that clinicians are employing clinical judgment to determine need for re-excision in more complex scenarios.
Our study has several potential limitations. First, our survey was brief and the response rate was low (\30 %). The survey was intentionally meant to be brief to maximize likelihood that busy surgeons targeted for participation would respond. It is possible that the response rate may have been higher if the survey was kept open for longer. Second, the scenarios presented were simple. Patient age, option to perform postoperative mammography, and options other than re-excision (i.e., mastectomy) were not included to save time needed to complete the survey. These details and options also were omitted because our goal was to obtain overall data on national surgical practice patterns for margin re-excision following publication of the guideline. Third, there is potential for bias in that there is no way to know if those who did not respond were a group unfamiliar with the recently published guideline or a group choosing not to follow the guideline. Lastly, though we did not include questions about practice patterns prior to publication of the guideline to ascertain whether actual changes were put into practice following publication of the guideline, historic data indicate that there has been a marked change in the alignment of the definition of margins and need for re-excision. 7, 8 
CONCLUSIONS
Our study documents that the majority of surgeons who responded were familiar with the recently published SSO-ASTRO guideline on margins, and most of these surgeons would re-excise margins when there is ink on tumor (positive margin). Most would not re-excise margins when ink did not touch the tumor, in agreement with the SSO-ASTRO guideline. However, for more complex scenarios, surgeons utilized their individual clinical judgment to determine whether re-excision was needed.
